CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond

Overview

Journal Trends Mol Med

Specialties General Medicine
Molecular Biology

Date 2017 Apr 19

PMID 28416139

Citations 47

Authors

ZeNan L Chang

Yvonne Y Chen

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptors (CARs) are versatile synthetic receptors that provide T cells with engineered specificity. Clinical success in treating B-cell malignancies has demonstrated the therapeutic potential of CAR-T cells against cancer, and efforts are underway to expand the use of engineered T cells to the treatment of diverse medical conditions, including infections and autoimmune diseases. Here, we review current understanding of the molecular properties of CARs, how this knowledge informs the rational design and characterization of novel receptors, the successes and shortcomings of CAR-T cells in the clinic, and emerging solutions for the continued improvement of CAR-T cell therapy.

Citing Articles

Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond.

Yang Z, Ha B, Wu Q, Ren F, Yin Z, Zhang H Front Immunol. 2025; 16:1544532.

PMID: 40046061 PMC: 11880241. DOI: 10.3389/fimmu.2025.1544532.

Cellular therapies in rheumatic and musculoskeletal diseases.

Franco-Fuquen P, Figueroa-Aguirre J, Martinez D, Moreno-Cortes E, Garcia-Robledo J, Vargas-Cely F J Transl Autoimmun. 2025; 10:100264.

PMID: 39931050 PMC: 11808717. DOI: 10.1016/j.jtauto.2024.100264.

Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.

Wang M, Yu F, Zhang Y Mol Cancer. 2025; 24(1):26.

PMID: 39827147 PMC: 11748575. DOI: 10.1186/s12943-024-02214-5.

Immunotherapies and Renal Injury.

Shaikh A Curr Opin Toxicol. 2024; 31.

PMID: 39086475 PMC: 11290437. DOI: 10.1016/j.cotox.2022.100362.

Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer.

Ma H, Das J, Prendergast C, de Jong D, Braumuller B, Paily J Curr Issues Mol Biol. 2023; 45(11):9019-9038.

PMID: 37998743 PMC: 10670348. DOI: 10.3390/cimb45110566.

References

Ma Z, Sharp K, Janmey P, Finkel T . Surface-anchored monomeric agonist pMHCs alone trigger TCR with high sensitivity. PLoS Biol. 2008; 6(2):e43. PMC: 2253636. DOI: 10.1371/journal.pbio.0060043. View

Carpenito C, Milone M, Hassan R, Simonet J, Lakhal M, Suhoski M . Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009; 106(9):3360-5. PMC: 2651342. DOI: 10.1073/pnas.0813101106. View

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

Gargett T, Yu W, Dotti G, Yvon E, Christo S, Hayball J . GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther. 2016; 24(6):1135-1149. PMC: 4923328. DOI: 10.1038/mt.2016.63. View

Long A, Haso W, Shern J, Wanhainen K, Murgai M, Ingaramo M . 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015; 21(6):581-90. PMC: 4458184. DOI: 10.1038/nm.3838. View

Romeo C, Seed B . Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell. 1991; 64(5):1037-46. DOI: 10.1016/0092-8674(91)90327-u. View

Gattinoni L, Finkelstein S, Klebanoff C, Antony P, Palmer D, Spiess P . Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005; 202(7):907-12. PMC: 1397916. DOI: 10.1084/jem.20050732. View

Ruella M, Barrett D, Kenderian S, Shestova O, Hofmann T, Perazzelli J . Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016; 126(10):3814-3826. PMC: 5096828. DOI: 10.1172/JCI87366. View

Stephan S, Taber A, Jileaeva I, Pegues E, Sentman C, Stephan M . Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol. 2014; 33(1):97-101. PMC: 4289408. DOI: 10.1038/nbt.3104. View

10.

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

11.

Kowolik C, Topp M, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N . CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006; 66(22):10995-1004. DOI: 10.1158/0008-5472.CAN-06-0160. View

12.

Pegram H, Park J, Brentjens R . CD28z CARs and armored CARs. Cancer J. 2014; 20(2):127-33. PMC: 4687893. DOI: 10.1097/PPO.0000000000000034. View

13.

Anton van der Merwe P, Zhang H, Cordoba S . Why do some T cell receptor cytoplasmic domains associate with the plasma membrane?. Front Immunol. 2012; 3:29. PMC: 3341999. DOI: 10.3389/fimmu.2012.00029. View

14.

Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L . HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997; 276(5319):1719-24. DOI: 10.1126/science.276.5319.1719. View

15.

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

16.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

17.

Yang Y, Jacoby E, Fry T . Challenges and opportunities of allogeneic donor-derived CAR T cells. Curr Opin Hematol. 2015; 22(6):509-515. PMC: 4636084. DOI: 10.1097/MOH.0000000000000181. View

18.

Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E . Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood. 2001; 97(1):63-72. DOI: 10.1182/blood.v97.1.63. View

19.

Li Y, Chen B, Wu P, Cheng T, Kao L, Tao M . Cutting Edge: mechanical forces acting on T cells immobilized via the TCR complex can trigger TCR signaling. J Immunol. 2010; 184(11):5959-63. DOI: 10.4049/jimmunol.0900775. View

20.

Maus M, Haas A, Beatty G, Albelda S, Levine B, Liu X . T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2014; 1(1):26-31. PMC: 3888798. DOI: 10.1158/2326-6066.CIR-13-0006. View